<DOC>
	<DOCNO>NCT03081689</DOCNO>
	<brief_summary>Phase II , single-arm , open-label multicenter study assess feasibility , safety efficacy combine neoadjuvant chemotherapy immunotherapy Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W resectable stage IIIA N2-NSCLC adult patient follow adjuvant treatment 1 year Nivolumab 240 mg IV Q2W 4 month Nivolumab 480mg Q4W 8 month .</brief_summary>
	<brief_title>Neo-Adjuvant Immunotherapy With Nivolumab Non Small Cell Lung Cancer Patients</brief_title>
	<detailed_description>Phase II , single-arm , open-label multicenter study assess feasibility , safety efficacy combine neoadjuvant chemotherapy immunotherapy Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W resectable stage IIIA N2-NSCLC adult patient follow adjuvant treatment 1 year Nivolumab 240 mg IV Q2W 4 month Nivolumab 480mg Q4W 8 month . Three cycle neoadjuvant chemotherapy combination nivolumab administer . After completion neoadjuvant therapy ( 3 cycle ) surgery , tumor assessment do . Patients allow leave study evidence progression . These patient may consider surgery . Report image response v pathological response rate evaluate . Patients eligible trial histological diagnosis cytologically proven operable resectable non-small-cell lung cancer . The total number patient include 46 23 participate site Spain . Accrual period 1.5 year inclusion last patient necessary achieve sample set protocol 46 patient . After patient treat 1 year adjuvant immunotherapy follow 3 year adjuvant treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . The subject eligible study histologically cytologically document NSCLC present stage IIIA disease 2 . Tumor consider resectable study entry 3 . Performance Status 0 1 4 . Screening laboratory value must meet follow criterion obtain within 14 day prior registration/inclusion i. WBC ≥ 2000/μL ii . Neutrophils ≥ 1500/μL iii . Platelets ≥ 100 x103/μL iv . Hemoglobin &gt; 9.0 g/dL v. Serum creatinine ≤ 1.5 x ULN creatinine clearance ( CrCl ) ≥ 40 mL/min ( use CockcroftGault formula ) : . Female CrCl = ( 140 age year ) x weight kg x 0.85 1 . 72 x serum creatinine mg/dL b . Male CrCl = ( 140 age year ) x weight kg x 1.00 1 . 72 x serum creatinine mg/dL vi . AST/ALT ≤ 3 x ULN vii . Total Bilirubin ≤ 1.5 x ULN ( except subject Gilbert Syndrome , total bilirubin &lt; 3.0 mg/dL ) viii . The patient need forced expiratory volume ( FEV1 ) ≥ 1.2 liter ix . INR/APTT within normal limit 5 . All patient notify investigational nature study sign write informed consent 6 . Patients age &gt; 18 year 7 . Women childbearing potential ( WOCBP ) must use appropriate method ( ) contraception . 8 . Women must breastfeed 9 . Men sexually active WOCBP must use contraceptive method failure rate le 1 % per year . 1 . All patient carry activate mutation TK domain EGFR variety alteration ALK gene . 2 . Patients active , know suspected autoimmune disease . 3 . Patients condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day randomization . 4 . Patients history interstitial lung disease include sympthomatic ILD ( Grade 34 ) 5 . Patients active malignancy require concurrent intervention 6 . Patients previous malignancy ( except nonmelanoma skin cancer , follow situ cancer : bladder , gastric , colon , endometrial , cervical/dysplasia , melanoma , breast ) exclude unless 7 . Any medical , mental psychological condition opinion investigator would permit patient complete study 8 . Patients prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCTLA4 antibody , 9 . Patients positive test hepatitis B virus surface antigen ( HBV sAg ) hepatitis C virus ribonucleic acid ( HCV antibody ) 10 . Patients known history test positive human immunodeficiency virus ( HIV ) 11 . Patients history allergy study drug component excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>